Abstract
Several statistical methods that are available in the literature to analyze postmarket safety databases, such as the U.S. Federal Drug Administration’s (FDA) adverse event reporting system (AERS), for identifying drug-event combinations with disproportionately high frequencies, are subject to high false discovery rates. Here, we propose a likelihood ratio test (LRT) based method and show, via an extensive simulation study, that the proposed method while retaining good power and sensitivity for identifying signals, controls both the Type I error and false discovery rates. The application of the LRT method to the AERS database is illustrated using two datasets; a small dataset consisting of suicidal behavior and mood change-related AE cases for the drug Montelukast, and a large dataset consisting of all possible AE cases reported to FDA during 2004–2008 for the drug Heparin. This article has supplementary material online.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
